araag2/HINT huggingface dataset:
Clinical trial NCT00387348 (phase 3, status: terminated)
Conditions: colorectal cancer, depression, esophageal cancer, extrahepatic bile duct cancer, fatigue, gallbladder cancer, gastric cancer, liver cancer, lung cancer, pancreatic cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, F32.A, F53.0, P91.4, Z13.31, Z13.32, K22.2, K22.81, Q39.4, P78.83, I85.00, I85.01, I85.10, C24.0, D13.5, R53.83, G93.3, R53.82, R53.0, T67.6XXS, T67.6XXA, T67.6XXD, C23, D37.6, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, D13.4, Z85.05, C22.8, C78.7, C22.9, D37.6, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, C25.3
Drugs: escitalopram oxalate, placebo
SMILES: CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    dsmb stopped study because placebo arm had more adverse events
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of any of the following for at least 4 weeks:

               -  Stage IIIB (with effusions) or stage IV non-small cell lung cancer

               -  Extensive stage small cell lung cancer

               -  Stage III or IV pancreatic cancer

               -  Stage IV liver cancer

               -  Stage III or IV gallbladder cancer

               -  Stage III or IV bile duct cancer

               -  Stage IV esophageal cancer

               -  Stage IV gastric cancer

               -  Second line stage IV colorectal cancer

          -  Meets diagnostic and Statistical Manual of Mental Disorders-4th Edition and Endicott
             criteria for major depressive disorder

          -  Duration of depressive symptoms ≥ 4 weeks

          -  Hamilton Depression D 17 (HAM-D 17) Scale ≥ 14

          -  No active suicidality requiring immediate care or psychiatric hospitalization

        PATIENT CHARACTERISTICS:

          -  Able to swallow pills

          -  No active substance abuse disorder (including alcohol abuse within the past 6 months),
             psychotic disorder or active psychotic symptoms, organic mental disorders, or bipolar
             disorder

          -  No clinical or laboratory evidence of hypothyroidism

          -  No hypercalcemia

          -  No severe anemia, defined as hemoglobin < 10 g/dL

          -  No history of multiple adverse drug reactions or allergy to study drugs

          -  Not pregnant

          -  No history of head trauma

          -  No history of epilepsy

        PRIOR CONCURRENT THERAPY:

          -  No other concurrent antidepressant medications or psychostimulants
Clinical trial NCT01670032 (phase 2/phase 3, status: completed)
Conditions: impetigo
ICD codes: L01.00, L01.02, L01.03, L01.09, L01.01
Drugs: experimental: cd07223 1.5 % topical gel bid, experimental: cd07223 1.5% topical gel tid, placebo comparator: cd07223 vehicle gel bid, placebo comparator: cd07223 vehicle gel tid
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female 2 years of age or older

          -  Clinical diagnosis of primary impetigo (bullous or non bullous)

          -  Minimum diameter of Target Lesion to be one centimeter measured either as length or
             width.

          -  Presence of at least one and no more than ten lesions per subject at the time of
             screening

          -  The infected lesions' total area (as determined by the Investigator) must be less than
             100 cm2 in total area for subjects 18 years of age or older, or up to a maximum of 2%
             total body surface area for subjects younger than 18 years of age.

          -  Skin Infection Rating Scale (SIRS) total score of the Target Lesion of at least 4

        Exclusion Criteria:

          -  Presence of other active skin diseases at or near the Target Lesion area to be treated

          -  A subject whose disease is so widespread or severe that, in the opinion of the
             investigator, oral antibiotic treatment is needed

          -  Signs and symptoms of another current infection requiring antibiotic treatment

          -  Tympanic temperature at Screening/Baseline exceeding 38 degrees Celsius (100.4 degrees
             Fahrenheit) in a pediatric subject or 37.8 degrees Celsius (100 degrees Fahrenheit) in
             an adult subject

          -  History of Hepatitis B or C, HIV/ AIDS, or other immunodeficiency disease

          -  Concurrent or recent scabies infection or lice infestation (pediculosis) of the scalp

          -  Use of systemic antibiotics or systemic steroids within 14 days prior to study entry.
             A history of three or more courses of systemic antibiotics within the 3 month period
             immediately prior to screening will also be considered exclusionary

          -  Use of topical antibiotics, topical antibacterials, topical antifungals or topical
             steroids within 14 days prior to study entry on any skin lesion (as deemed significant
             by the Investigator by virtue of the lesion's nature and/or position to impact on the
             effectiveness of the study drug)

          -  Participation in any other clinical study or use of any investigational drugs or
             investigational device within 30 days prior to enrollment

          -  Presence of secondarily infected traumatic lesions (e.g. surgical wounds,
             animal/insect bites, burns, lacerations and abrasions).

          -  Another family member in same household currently enrolled in this study or another
             family member in the same household with active impetigo
Clinical trial NCT00621842 (phase 3, status: completed)
Conditions: bipolar disorder, depression, bipolar
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32, F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: lamotrigine regular tablet formulation, lamotrigine novel formulation
SMILES: NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1, NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Age 60 Years or older

          -  BP Disorder-I or II: Depressive episode (DSM -IV-TR; SCID-I/P)

          -  HAM-D score > 18 (GRID-HAM-D 24-item version)

          -  Availability of an Informant is encouraged but not required for study participation

        Exclusion Criteria:

          -  Chronic psychotic conditions, ie. schizophrenia, schizoaffective disorder, delusional
             disorder

          -  Contraindication to lamotrigine (Physician interview, medical assessment)

          -  Documented history of intolerance to lamotrigine

          -  Patients who have previously failed to respond to at least 12 weeks of treatment with
             lamotrigine

          -  Active substance dependence (SCID-I/P) or substance-related safety issues or PI
             concerns

          -  Mood Disorder Due to a General Medical Condition or Treatment (Physician interview)

          -  Rapid cycling (Physician interview): As defined in DSM-IV: At least 4 episodes of mood
             disturbance in the previous 12 months that meet criteria for a Major Depressive,
             Manic, Mixed or Hypomanic Episode. Episodes are distinguished either by partial or
             full remission for at least 2 months or by a switch to an episode of opposite polarity

          -  Dementia (by DSM-IV or brain degenerative diseases; Physician interview);

          -  Inability to communicate in English (i.e., interview cannot be conducted without an
             interpreter; subject largely unable to understand questions and cannot respond in
             English)

          -  Clinically significant sensory impairment (i.e., cannot see well enough to read
             consent or visually-presented material; cannot hear well enough to cooperate with
             interview; Physician interview)

          -  Recent history of cardiovascular, peripheral vascular events or stroke

          -  High risk for suicide (e.g., active SI or current intent or plan)

          -  Inpatient status
Clinical trial NCT00397631 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: sitagliptin 100 mg q.d./pioglitazone 30 mg q.d, comparator: placebo to match sitagliptin 100 mg q.d./pioglitazone 30 mg q.d.
SMILES: N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        General Inclusion Criteria:

          -  Patients ≥18 years old with Type 2 Diabetes Mellitus (a specific type of diabetes)

        General Exclusion Criteria:

          -  Patient has a history of type 1 diabetes mellitus or history of ketoacidosis

          -  Patient was on antihyperglycemic agent therapy (oral or insulin) within the prior 4
             months

          -  Patient was on >4 weeks (cumulatively) of antihyperglycemic therapy (oral or insulin)
             over the prior 2 years
Clinical trial NCT00427219 (phase 2/phase 3, status: completed)
Conditions: benign prostatic hypertrophy
ICD codes: J35.3, J35.1, J35.2, N28.81, N62, N85.2, J34.3
Drugs: ozarelix/placebo, placebo
SMILES: CCCC[C@H](NC(=O)[C@@H](CCCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        - All of the following questions must be answered "Yes" at Visit 1 in order for the patient
        to participate in the study.

          -  Is the patient at least 50 years old?

          -  Does the patient have clinical signs and symptoms consistent with BPH?

          -  Does the patient have an IPSS ³13 at screening (prior to placebo run in)?

          -  Does the patient have a peak urinary flow rate (Qmax) of 4-15 mL/sec established on a
             voided volume of at least 125 mL?

          -  Is the patient willing to agree not to use any other approved or experimental
             pharmacologic BPH treatments including alpha blockers, 5-alpha reductase inhibitors,
             anti-cholinergic preparations or herbal preparations at any time during the study?

        Exclusion Criteria: All of the following questions must be answered "No" at Visit 1 in
        order for the patient to participate in the study.

          -  Does the patient have a history of prostate cancer or a serum PSA >10 ng/mL?

          -  Has the patient had prior prostate or bladder surgery, pelvic surgery (excluding
             hernia repair), pelvic radiation or lower urinary tract malignancy?

          -  Does the patient have a prevoid total bladder volume assessed by ultrasound > 550 mL?

          -  Does the patient have a residual urine volume > 350 mL by ultrasound?

          -  Has the patient taken or is currently taking any of the following:
Clinical trial NCT01500083 (phase 3, status: completed)
Conditions: indolent non-hodgkin's lymphoma, chronic lymphocytic leukemia
ICD codes: C91.11, C91.12, C91.10
Drugs: bendamustine at a dose of 100 mg/m2, bendamustine at a dose of 120 mg/m2
SMILES: CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl, CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl
Eligibility criteria:

        Inclusion Criteria for iNHL:

          -  The patient has biopsy-confirmed diagnosis of indolent B-cell NHL documented as
             relapsed or refractory iNHL (following rituximab-based therapy).

          -  The patient has one of the following types of indolent B-cell lymphoma:

               -  follicular lymphoma grade 1, 2, or 3A

               -  marginal zone lymphoma

               -  lymphoplasmacytic lymphoma

               -  small lymphocytic lymphoma

          -  The patient has adequate haematologic function (unless abnormalities are related to
             lymphoma involvement of the bone marrow or hypersplenism caused by lymphoma).

        Inclusion Criteria for CLL:

          -  The patient has previously confirmed (according to WHO criteria) untreated symptomatic
             chronic B-cell lymphocytic leukemia Binet Stage B or Binet Stage C or Rai stage II to
             IV in need of medical treatment.

          -  The patient has an Eastern Cooperative Oncology Group (ECOG) performance status of
             0-2.

        Exclusion Criteria:

          -  The patient has participated in a clinical study <30 days prior to the Screening
             Visit.

          -  The patient has one or more of the following conditions:

               -  active transformed lymphoma

               -  any history of central nervous system or leptomeningeal lymphoma

               -  an active malignancy other than the target cancer within the past 5 years

               -  human immunodeficiency virus

          -  The patient is, in the investigator's opinion, unlikely to comply with the protocol or
             is unsuitable for any reason.

        Other inclusion and exclusion criteria may apply.
Clinical trial NCT00631319 (phase 3, status: completed)
Conditions: chronic pain
ICD codes: G89.29, G89.4, R39.82, G89.22, G89.28, G89.21, G89.3
Drugs: oros hydromorphone, placebo
SMILES: [H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria

          -  Primary clinic diagnosis of osteoarthritis pain of the hip or of the knee for at least
             6 months

          -  Patients required daily opioid medication to treat their chronic osteoarthritis pain

        Exclusion Criteria

          -  Joint replacement of the hip or of the knee that is the primary source of
             osteoarthritis Pain

          -  History drug or alcohol abuse

          -  Fibromyalgia

          -  Patients who have major depression or anxiety

          -  Women who are pregnant or breast feeding
Clinical trial NCT00062673 (phase 3, status: completed)
Conditions: depression, cognition
ICD codes: F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: duloxetine, placebo
SMILES: CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  You must be able to visit the doctor's office for clinic visits, tests, and
             procedures.

          -  You must have been diagnosed with major depression, and have had at least one other
             episode in the past.

        Exclusion Criteria:

          -  You have a current or previous major psychiatric disorder other than depression, such
             as bipolar disorder, schizophrenia, or other psychotic disorder.

          -  You have taken a drug within the last 30 days that has not been approved for use by
             governmental authorities.
Clinical trial NCT00306540 (phase 3, status: completed)
Conditions: post-traumatic stress disorder
ICD codes: F43.10, F43.11, F43.12
Drugs: quetiapine fumarate, quetiapine fumarate placebo
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12, OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Hospitalised and non-hospitalised patients / Veteran or Civilian / Have had symptoms
             of PTSD for a minimum of 12 months prior to giving consent to the study

        Exclusion Criteria:

          -  History of psychotic condition / quetiapine or other anti-psychotics not worked
             previously / Taking prohibited medications (mood stabilizers / substance abuse)
Clinical trial NCT01294215 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: nifedipine (adalat, baya1040)
SMILES: COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  20 years or older

          -  Japanese male or female

          -  Outpatient with essential hypertension

          -  Patients who are treated with Adalat CR 40 mg od and at least one antihypertensive
             drug (other than Ca antagonists) for 4 weeks or more before entry in this study

        Exclusion Criteria:

          -  Patients whose sitting diastolic blood pressure (DBP) is 110 mm Hg or more

          -  Patients with secondary hypertension or hypertensive emergency
Clinical trial NCT00453063 (phase 3, status: completed)
Conditions: seasonal allergic rhinitis
ICD codes: J30.2
Drugs: mometasone furoate, placebo
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Must be 12 years of age or older, of either sex and of any race.

          -  Must have at least a 2-year documented history of SAR which exacerbates during the
             study season.

          -  Must have a positive skin-prick test response to an appropriate seasonal allergen at
             Screening (Visit 1). Immunoglobulin E (IgE)-mediated hypersensitivity to an
             appropriate seasonal allergen (ie, prevailing trees and/or grasses) must be documented
             by a positive response to the skin prick test with wheal diameter at least 3 mm larger
             than diluent control after 20 minutes.

          -  Must be clinically symptomatic at the Screening Visit.

          -  Must be clinically symptomatic at the Baseline Visit.

          -  Must be in general good health as confirmed by routine clinical and laboratory testing
             and electrocardiogram (ECG) results. Clinical laboratory test (complete blood count
             [CBC], blood chemistries, and urinalysis) must be within normal limits or clinically
             acceptable to the investigator and the sponsor.

          -  Must be free of any clinically significant disease, other than SAR, that would
             interfere with the study evaluations.

        Exclusion Criteria:

          -  A history of anaphylaxis and/or other severe local reaction(s) to skin testing.

          -  A subject with asthma who requires chronic use of inhaled or systemic corticosteroids.

          -  Current or history of frequent, clinically significant sinusitis or chronic purulent
             postnasal drip.

          -  A subject with rhinitis medicamentosa.

          -  A history of allergies to more than two classes of medications or who are allergic to
             or cannot tolerate nasal sprays.

          -  A subject who has had an upper respiratory tract or sinus infection that required
             antibiotic therapy without at least a 14-day washout prior to the Screening Visit, or
             who has had a viral upper respiratory infection within 7 days before the Screening
             Visit.

          -  A subject who has nasal structural abnormalities, including large nasal polyps and
             marked septal deviations, which significantly interfere with nasal air flow.

          -  A subject who, in the opinion of the investigator, is dependent on nasal, oral, or
             ocular decongestants, nasal topical antihistamines, or nasal steroids.
Clinical trial NCT00329238 (phase 3, status: completed)
Conditions: thromboembolism
ICD codes: O88.22, O88.23, O88.211, O88.212, O88.213, O88.219
Drugs: dabigatran, warfarin
SMILES: CCCCCCOC(=O)\N=C(\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1, S1SSSSSSS1
Eligibility criteria:

        Inclusion criteria:

        Inclusion_Criteria

          -  Acute symptomatic deep vein thrombosis (DVT)

          -  Pulmonary embolism (PE) 3-12 months prior to screening, which has been documented by
             objective testing

        Exclusion criteria:

        Exclusion_Criteria

          -  Symptomatic DVT or PE at screening Interruption of anticoagulant therapy for 2 or more
             weeks during the 3-12 months of treatment for the prior VTE.

          -  Patients who in the investigators judgement are perceived as having an excessive risk
             of bleeding Elevated Aspartate aminotransferase (AST) or Alanine tranminase (ALT) > 2x
             ULN

          -  Severe renal impairment (estimated creatinine clearance <= 30 ml/min)
Clinical trial NCT00544076 (phase 3, status: terminated)
Conditions: prostate cancer, male erectile disorder, stage i prostate cancer, stage ii prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5, F52.21, C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5, C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: sildenafil citrate, alprostadil
SMILES: CCCC1=NN(C)C2=C1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(C)CC1, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O
Reason stopped: 
    accrual too slow
  
Eligibility criteria:

        Inclusion Criteria

          -  All patients undergoing BNS-RAP for prostate cancer will be asked to participate

          -  Ability to achieve erections sufficient for intercourse prior to surgery and an
             SHIMS-5 score of >= 22

          -  Must maintain follow up care at COH for visits 1, 3, 6, 9, 12, and 18 months post
             surgery

          -  Participants willing to participate on study for a minimum of 18 months

          -  Consented participant on the Prostate database study (protocol 00149)

          -  Patients must have a clinical stage of < T3

          -  Gleason score < 8 on post-operative pathological sample prior to randomization

        Exclusion Criteria

          -  Metastatic disease

          -  Coronary artery disease on nitrate therapy (including oral sublingual nitrates)

          -  Unable to maintain follow up visits at COH at 1, 3, 6, 9, 12, and 18 months
             post-operatively

          -  Pathology diagnosis >= pT3

          -  Prior hormonal treatment use for prostate cancer or low serum testosterone

          -  Allergy to prostaglandin PGE1, Lidocaine, or Viagra

          -  Gleason score >= 8 on post-operative pathological sample prior to randomization

          -  Concomitant use of cytochrome P450 3AY inhibitors (cimetidine, erythromycin,
             ketoconazole, or protease inhibitors)

          -  SHIMS-5 score =< 21